GrapheneDx, General Graphene Corp and Sapphiros Enter Into Strategic Partnership to Industrialize Graphene-Based Biosensors to Revolutionize Point of Care and Consumer Diagnostics
GrapheneDx is an in vitro diagnostics company focused on improving diagnostic capability at the point-of-care and in consumer settings.
- GrapheneDx is an in vitro diagnostics company focused on improving diagnostic capability at the point-of-care and in consumer settings.
- The company is an expert in functionalizing graphene to create graphene field effect transistors (GFETs), which are biosensors that can be used to detect disease in biological samples.
- Sapphiros operates a proprietary, industry-leading reel-to-reel EVM facility for point-of-care and consumer diagnostics, with a capacity of 5 billion tests per year.
- Combined with General Graphene's impressive scale and graphene expertise, Sapphiros will accelerate the industrialization and commercialization of GrapheneDx's biosensor technology."